To further validate the therapeutic role of OTUD6A oligonucleotide in vivo, we established a patient-derived xenograft (PDX) model with a surgical specimen of radically resected prostate tumor from a patient with a postoperative pathological diagnosis of acinar adenocarcinoma, Gleason score 5 + 4. This evidence concerns the gene OTUD6A and prostate neoplasm.